
Artelo Biosciences ARTL
$ 4.85
0.0%
Annual report 2025
added 02-24-2026
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
2.02 M |
Market Cap[1] |
$ 9.79 M |
EBITDA (LTM) |
$ -9.36 M |
P/E (LTM) |
-10.1 |
P/S (LTM) |
- |
EPS (LTM) |
-0.48 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | ||
|
Ascendis Pharma A/S
ASND
|
$ 220.9 | - | $ 5 B | Nasdaq Global Select Market | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | ||
|
BioNTech SE
BNTX
|
$ 88.77 | - | $ 27.2 B | Nasdaq Global Select Market | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | ||
|
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
Cabaletta Bio
CABA
|
$ 2.78 | - | $ 279 M | Nasdaq Global Select Market | ||
|
Aileron Therapeutics
ALRN
|
- | 10.36 % | $ 9.8 M | Nasdaq Global Select Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | ||
|
Amphastar Pharmaceuticals
AMPH
|
$ 19.57 | - | $ 915 M | Nasdaq Global Select Market | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
$ 8.31 | - | $ 111 M | Nasdaq Global Market | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | ||
|
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | ||
|
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | ||
|
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | ||
|
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | ||
|
Autolus Therapeutics plc
AUTL
|
$ 1.33 | - | $ 339 M | Nasdaq Global Select Market | ||
|
Atreca
BCEL
|
- | -11.76 % | $ 5.79 M | Nasdaq Global Select Market | ||
|
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market | ||
|
Harmony Biosciences Holdings
HRMY
|
$ 27.59 | - | $ 1.59 B | Nasdaq Global Select Market | ||
|
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | ||
|
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | ||
|
Cara Therapeutics
CARA
|
- | -3.03 % | $ 260 M | Nasdaq Global Market,SPB | ||
|
ChemoCentryx
CCXI
|
- | - | $ 3.74 B | Nasdaq Global Select Market,SPB | ||
|
Immatics N.V.
IMTX
|
$ 9.74 | - | $ 613 M | Nasdaq Global Select Market | ||
|
InMed Pharmaceuticals
INM
|
$ 0.7 | - | $ 1.71 M | Nasdaq Capital Market | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
Avid Bioservices
CDMO
|
- | - | $ 789 M | Nasdaq Capital Market | ||
|
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | ||
|
Ironwood Pharmaceuticals
IRWD
|
$ 3.19 | - | $ 507 M | Nasdaq Global Select Market | ||
|
Iterum Therapeutics
ITRM
|
$ 0.17 | - | $ 3.35 M | Nasdaq Global Select Market | ||
|
Johnson & Johnson
JNJ
|
$ 239.93 | - | $ 578 B | NYSE,SPB | ||
|
Bellerophon Therapeutics
BLPH
|
- | -74.18 % | $ 955 K | Nasdaq Capital Market | ||
|
Karyopharm Therapeutics
KPTI
|
$ 5.21 | - | $ 635 K | Nasdaq Global Select Market | ||
|
Keros Therapeutics
KROS
|
$ 11.34 | - | $ 422 M | Nasdaq Global Select Market | ||
|
CRISPR Therapeutics AG
CRSP
|
$ 47.09 | - | $ 4.23 B | Nasdaq Global Market,SPB | ||
|
Arbutus Biopharma Corporation
ABUS
|
$ 4.53 | - | $ 868 M | Nasdaq Global Select Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.